MX380358B - Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. - Google Patents

Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.

Info

Publication number
MX380358B
MX380358B MX2016014000A MX2016014000A MX380358B MX 380358 B MX380358 B MX 380358B MX 2016014000 A MX2016014000 A MX 2016014000A MX 2016014000 A MX2016014000 A MX 2016014000A MX 380358 B MX380358 B MX 380358B
Authority
MX
Mexico
Prior art keywords
antibody
igf
target
cancer treatment
specific vehicle
Prior art date
Application number
MX2016014000A
Other languages
English (en)
Other versions
MX2016014000A (es
Inventor
Alain Robert
Charlotte Beau-Larvor
Liliane Goetsch
Matthieu Broussas
Thierry Champion
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2016014000A publication Critical patent/MX2016014000A/es
Publication of MX380358B publication Critical patent/MX380358B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se refiere a un anticuerpo, particularmente con un anticuerpo monoclonal, capaz de unirse a IGF-1R, así como a las secuencias de aminoácidos y ácidos nucleicos que codifican para el mencionado anticuerpo. En uno de sus aspectos, la invención se relaciona con un anticuerpo o con un fragmento de unión al antígeno del mismo, capaz unirse a IGF-1R y, al inducir la incorporación de IGF-1R, de interiorizarse en la célula. La invención también comprende el uso de dicho anticuerpo a manera de un producto o vehículo con especificidad de objetivo en conjugación con otros compuestos anticancerígenos como toxinas, radioelementos o fármacos, y el uso del mismo para el tratamiento contra ciertos tipos cánceres.
MX2016014000A 2014-04-25 2015-04-27 Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer. MX380358B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984160P 2014-04-25 2014-04-25
PCT/EP2015/059050 WO2015162292A1 (en) 2014-04-25 2015-04-27 Igf-1r antibody and its use as addressing vehicle for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2016014000A MX2016014000A (es) 2017-05-30
MX380358B true MX380358B (es) 2025-03-12

Family

ID=53373391

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014000A MX380358B (es) 2014-04-25 2015-04-27 Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
MX2021002144A MX2021002144A (es) 2014-04-25 2016-10-25 Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002144A MX2021002144A (es) 2014-04-25 2016-10-25 Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.

Country Status (29)

Country Link
US (2) US10202458B2 (es)
EP (2) EP3783033A1 (es)
JP (2) JP6835591B2 (es)
KR (3) KR20220018620A (es)
CN (2) CN112851808B (es)
AU (1) AU2015250760C1 (es)
BR (1) BR112016024575B1 (es)
CA (1) CA2946795C (es)
CY (1) CY1123743T1 (es)
DK (1) DK3134438T3 (es)
ES (1) ES2841249T3 (es)
HR (1) HRP20202047T1 (es)
HU (1) HUE052223T2 (es)
IL (2) IL248357B (es)
LT (1) LT3134438T (es)
MA (2) MA39378B2 (es)
MX (2) MX380358B (es)
MY (1) MY182444A (es)
NZ (1) NZ725423A (es)
PL (1) PL3134438T3 (es)
PT (1) PT3134438T (es)
RS (1) RS61379B1 (es)
RU (1) RU2698977C2 (es)
SA (1) SA516380131B1 (es)
SI (1) SI3134438T1 (es)
TN (1) TN2016000445A1 (es)
UA (1) UA122390C2 (es)
WO (1) WO2015162292A1 (es)
ZA (1) ZA201607095B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016024619A2 (pt) * 2014-04-25 2017-10-10 Pf Medicament conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer
JP6968790B2 (ja) 2015-10-26 2021-11-17 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ発現癌の処置のための組成物
EP3565842A1 (en) * 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
JP7312168B2 (ja) 2017-11-13 2023-07-20 クレッシェンド、バイオロジックス、リミテッド Ｃｄ１３７に結合するシングルドメイン抗体
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
KR102858995B1 (ko) 2018-09-27 2025-09-11 피에르 파브르 메디카먼트 설포말레이미드계 링커 및 상응하는 컨쥬게이트
WO2020079229A1 (en) * 2018-10-19 2020-04-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3150807A1 (en) 2019-09-04 2021-03-11 Y-Biologics Inc. Anti-vsig4 antibody or antigen binding fragment and uses thereof
EP4353220A1 (en) 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
FR2661000B1 (fr) 1990-04-12 1992-08-07 Aerospatiale Machine d'essais d'eprouvettes en cisaillement.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5561427A (en) 1994-12-30 1996-10-01 Psc Inc. Analog to digital converter with continuous conversion cycles and large input signal range
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
EA200802061A1 (ru) * 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
CA2698541C (en) 2007-10-19 2018-01-09 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
AR080793A1 (es) * 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
KR20140138353A (ko) * 2011-04-19 2014-12-03 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체

Also Published As

Publication number Publication date
AU2015250760A1 (en) 2016-11-03
SA516380131B1 (ar) 2019-12-04
ES2841249T3 (es) 2021-07-07
LT3134438T (lt) 2021-01-11
BR112016024575A2 (pt) 2017-10-10
TN2016000445A1 (en) 2018-04-04
MA39378B2 (fr) 2021-02-26
RU2016145277A (ru) 2018-05-28
RS61379B1 (sr) 2021-02-26
EP3134438B1 (en) 2020-09-30
KR20200128210A (ko) 2020-11-11
CN106459204B (zh) 2021-02-02
CN112851808B (zh) 2024-12-06
AU2015250760B2 (en) 2020-10-22
EP3783033A1 (en) 2021-02-24
US20170267766A1 (en) 2017-09-21
EP3134438A1 (en) 2017-03-01
CN106459204A (zh) 2017-02-22
MA53069B1 (fr) 2022-04-29
US11365259B2 (en) 2022-06-21
JP2021073279A (ja) 2021-05-13
IL248357A0 (en) 2016-11-30
AU2015250760C1 (en) 2023-11-16
KR102357032B1 (ko) 2022-02-08
IL248357B (en) 2020-05-31
UA122390C2 (uk) 2020-11-10
HRP20202047T1 (hr) 2021-02-19
MX2016014000A (es) 2017-05-30
RU2016145277A3 (es) 2018-12-13
CA2946795A1 (en) 2015-10-29
HUE052223T2 (hu) 2021-04-28
PL3134438T3 (pl) 2021-04-06
IL274226A (en) 2020-06-30
WO2015162292A1 (en) 2015-10-29
MY182444A (en) 2021-01-25
JP2017513898A (ja) 2017-06-01
SI3134438T1 (sl) 2021-04-30
DK3134438T3 (da) 2020-12-07
KR20160145110A (ko) 2016-12-19
MX2021002144A (es) 2021-03-09
MA39378A1 (fr) 2018-05-31
JP6835591B2 (ja) 2021-02-24
PT3134438T (pt) 2020-12-31
JP7191134B2 (ja) 2022-12-16
KR20220018620A (ko) 2022-02-15
MA53069A1 (fr) 2021-10-29
NZ725423A (en) 2023-07-28
CY1123743T1 (el) 2022-03-24
KR102177436B1 (ko) 2020-11-12
US10202458B2 (en) 2019-02-12
CN112851808A (zh) 2021-05-28
ZA201607095B (en) 2020-07-29
US20190330353A1 (en) 2019-10-31
CA2946795C (en) 2021-03-30
RU2698977C2 (ru) 2019-09-02
BR112016024575B1 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
MX380358B (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
MY174259A (en) Antigen binding protein and its use as addressing product for the treatment of cancer
PH12017500890A1 (en) Antibody drug conjugates
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
ZA201904218B (en) Anti¿ccr7 antibody drug conjugates
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
TW201613643A (en) Anti-CDH6 antibody drug conjugates
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
NZ748976A (en) Bispecific binding proteins and uses thereof
HK1257056A1 (zh) 抗dll3抗体药物缀合物以及使用方法
UA117364C2 (uk) Похідні аматоксину
AR093357A1 (es) Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
MX2016013857A (es) Anticuerpos anti-rnf43 novedosos y metodos de uso.
PE20160528A1 (es) Anticuerpos
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
MX2016008478A (es) Nuevo anticuerpo anti adam17 y su uso en el tratamiento del cancer.
BR112017013420A2 (pt) anticorpo adam17 humanizado
SA517390221B1 (ar) Igf-1r الجسم المضاد لـ واستخدامه في تشخيص سرطان
AR107223A1 (es) Anticuerpos dirigidos contra upk1b y métodos para su uso
BR112018067897A2 (pt) imunoglobulinas modificadas com ligação de fcrn alterada
TH158975A (th) องค์ประกอบและวิธีการสำหรับแอนติบอดีซึ่งกำหนดเป้าหมายต่อแฟคเตอร์ พี (factor p)
TH146212A (th) โปรตีนเข้าจับแอนติเจนและการใช้ของมันในฐานะเป็นผลิตภัณฑ์แก้ปัญหาสำหรับการบำบัดมะเร็ง
PE20142189A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9